MIPI Score - MCL Risk Group From Four Bedside Inputs

The MIPI score is the Mantle Cell Lymphoma International Prognostic Index, a bedside tool that uses age, ECOG performance status, serum LDH, and the white blood cell count to assign a low, intermediate, or high risk band for advanced-stage mantle cell lymphoma. It helps clinicians set prognosis expectations, choose between standard immunochemotherapy, intensified regimens, and transplant, and frame shared decisions with the patient.

• • Newly diagnosed MCL triage: A hematology team choosing between R-CHOP plus cytarabine, R-DHAP, or BTK inhibitor therapy.
• • Transplant eligibility discussion: An oncologist framing whether autologous stem cell transplant is reasonable for a fit older patient.
• • Clinical trial stratification: A research coordinator entering the MIPI band as a stratification factor for a frontline protocol.

The index was derived on 455 advanced-stage mantle cell lymphoma patients from the European MCL Network. The 5.7 and 6.2 cut-offs were chosen so the low-risk band captures 60 percent 5-year overall survival, the intermediate band a 51-month median, and the high-risk band a 29-month median.

The MIPI is a clinical index, not a diagnostic test. It does not replace the biopsy, the Ki-67 index, or the cyclin D1 FISH that confirm the diagnosis. It gives the team a transparent weighted sum to record in the chart note.

When the team follows a hematologic malignancy with serial tumour markers, the PSA Doubling Time Calculator shows how a different oncology score (PSADT) is read off dated blood work.

The calculator walks through the four clinical variables, normalises them into the same units used in the Hoster 2008 paper, and applies the published weighted sum. The total is matched to the 5.7 and 6.2 cut-offs to assign the risk band, and the optional Ki-67 percentage is added for the combined biological MIPI when one is provided.

• Age: The 0.03535 weight makes each decade add about 0.35 points.
• ECOG > 1 indicator: An indicator term worth 0.6978 points that turns on when performance status is 2, 3, or 4.
• log10(LDH/ULN): A ratio of 1 contributes 0 points; a ratio of 10 contributes about 1.37 points.
• log10(WBC): A WBC of 1 contributes 0 points; a WBC of 100 contributes about 1.88 points.

The numeric result is a continuous score between 0 and 10. The ECOG term is the only one with a discontinuity: ECOG 0 or 1 keeps the indicator at 0, while ECOG 2, 3, or 4 turns it on. This is the original Hoster 2008 specification, not a simplification.

According to Hoster et al. (Blood 2008), a MIPI score below 5.7 places advanced-stage mantle cell lymphoma patients in a low-risk band with 60 percent 5-year overall survival, a score between 5.7 and 6.2 in an intermediate band with a 51-month median, and a score of 6.2 or higher in a high-risk band with a 29-month median.

Because high-dose cytarabine, platinum-based salvage, and many transplant conditioning regimens all depend on renal function, the GFR Calculator is the usual next step the team runs before picking and dosing the induction regimen.

The four clinical variables each capture a different angle on the underlying lymphoma biology and the patient's ability to tolerate therapy.

All four variables are weighted, so the score is not a simple count. A 55-year-old with ECOG 3 and a high LDH can land in the intermediate or high band even with a normal WBC, just as a young patient with massive lymphocytosis can land in the high band with a near-normal ECOG.

When the biopsy also reports a Ki-67 proliferation index, the combined biological MIPI extends the clinical score. The 2014 European MCL Network validation confirmed the original bands in 958 patients, and the 2016 update added MIPIb on top.

According to Hoster et al. (J Clin Oncol 2014), the original MIPI bands were confirmed across 958 patients and independent treatment cohorts, supporting the 5.7 and 6.2 thresholds used in the calculator.

When the patient is later admitted on heparin for central line care and the platelet count falls, the 4TS Score is the structured HIT pretest probability tool the team uses at the bedside.

Treat the calculator as a chart note aid. Pull the four clinical variables from the workup, enter them in their published units, and read the risk band alongside the patient's treatment plan.

1. 1 Document age and ECOG: Enter the age and the ECOG status 0 to 4. Status 0 or 1 keeps the indicator term at 0; status 2, 3, or 4 adds 0.6978 points.
2. 2 Pull the serum LDH and local ULN: Use the LDH from the diagnostic chemistry panel and the ULN from the same lab.
3. 3 Add the white blood cell count: Enter the WBC in 10^9 per litre, the same as 10^3 per microlitre. A WBC of 8,000 cells per microlitre is entered as 8.
4. 4 Add Ki-67 when the biopsy is back: Enter the percentage of Ki-67 positive cells from the diagnostic biopsy to also surface MIPIb.
5. 5 Read the risk band and survival reference: Match the total to the 5.7 and 6.2 cut-offs and record the band in the chart note.

A 67-year-old, ECOG 1, LDH 380 on 200 U/L ULN, WBC 18. Score = 0.03535 x 67 + 1.367 x log10(1.9) + 0.9393 x log10(18) = 2.37 + 0.38 + 1.13 = 3.88, low risk. MIPIb with Ki-67 35 percent = 6.67.

When the team is also documenting a baseline performance status for longitudinal follow-up, the BASDAI Calculator shows the same 0 to 10 scoring idea applied to ankylosing spondylitis.

A MIPI review can be done in the chart with a pen, but a calculator makes the weighted sum consistent, traceable, and easier to defend at tumour board.

• • Standardised risk grouping across providers: Medical oncologists, residents, and advanced practice providers use the same four variables and cut-offs, reducing drift between reviewers.
• • Transparent record-keeping: Each input, the LDH to ULN ratio, and the final score can be quoted in the chart note.
• • Quick link to the published survival bands: The calculator pairs the score with the Hoster 2008 median overall survival for each band.
• • Optional combined biological MIPI: Adding the Ki-67 percentage computes the combined biological MIPI alongside the clinical score, which is what most European MCL Network trials now publish.

The original MIPI was built before BTK inhibitors and CAR-T became frontline options for mantle cell lymphoma, so the band is a baseline. The tool is also useful for teaching rounds: trainees can see how each variable moves the score.

Several things can move the score up or down, and a few should be checked before the band is written into the chart.

• • The clinical MIPI was derived on patients treated with CHOP-like induction. Modern BTK inhibitors, bispecifics, and CAR-T have changed the survival curves, especially in the high-risk band.
• • The score is a clinical index, not a diagnostic test. It does not replace the biopsy, the cyclin D1 FISH, the SOX11 immunohistochemistry, or the TP53 sequencing that the modern workup usually includes.

Bleeding risk, kidney function, comorbidity burden, and goals of care matter for what to do with the band, but those are not part of the scoring tool. The 5.7 and 6.2 cut-offs pair the score with the Hoster 2008 median overall survival.

According to Hoster et al. (J Clin Oncol 2016), the combined biological MIPI is 0.02142 times the clinical MIPI plus 0.18829 times the Ki-67 proliferation index in percent, and the combined index improves prognostic discrimination in the European MCL Network trials.

When the team wants a second opinion on liver involvement from chemotherapy, the APRI Calculator gives the same kind of structured weighted sum for hepatic fibrosis from AST and platelet count.